Quick Answer
Royalty Pharma plc reported Operating Income of $1.56 billion for fiscal year 2025.
Royalty Pharma plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $1.56B | +20.7% |
| 2024 | $1.29B | -13.4% |
| 2023 | $1.49B | +385.9% |
| 2022 | $307.06M | -78.5% |
| 2021 | $1.43B | -10.3% |
| 2020 | $1.60B | -39.2% |
| 2019 | $2.62B | +92.3% |
| 2018 | $1.36B | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $427.16M | -41.9% | +103.6% |
| June 30, 2025 | $209.80M | -22.2% | -60.7% |
| March 31, 2025 | $534.18M | +824.1% | -27.3% |
| September 30, 2024 | $735.07M | +385.4% | +172.6% |
| June 30, 2024 | $269.63M | +8.4% | +465.5% |
| March 31, 2024 | -$73.77M | -115.4% | -148.7% |
| September 30, 2023 | $151.44M | -21.2% | -39.1% |
| June 30, 2023 | $248.84M | -34.1% | -48.0% |
- Royalty Pharma plc showed an increase of +20.7% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Royalty Pharma plc’s operating income has grown by 14.3% (from $1.36 billion to $1.56 billion).
- The most recent figure is from Royalty Pharma plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: